Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Discovery | - | 22 Aug 2024 | |
| Chronic cough | Discovery | - | 22 Aug 2024 | |
| Digestive System Disorders | Discovery | - | 22 Aug 2024 | |
| Endocrinology and Metabolic Disease | Discovery | - | 22 Aug 2024 | |
| Immune System Diseases | Discovery | - | 22 Aug 2024 | |
| Infectious Diseases | Discovery | - | 22 Aug 2024 | |
| Neoplasms | Discovery | - | 22 Aug 2024 | |
| Nervous System Diseases | Discovery | - | 22 Aug 2024 | |
| Other Diseases | Discovery | - | 22 Aug 2024 | |
| Periodontal Diseases | Discovery | - | 22 Aug 2024 |





